US 12,276,000 B2
Methods for predicting the risk of developing pulmonary colonization/infection by Pseudomonas aeruginosa
Geneviève Hery-Arnaud, Brest (FR); Jérôme Mounier, Plouzané (FR); Charles-Antoine Guilloux, Brest (FR); Patricia Lepage, Jouy-en-Josas (FR); Stanislas Mondot, Jouy-en-Josas (FR); and Marlène Keravec, Plouzané (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris (FR); CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST, Brest (FR); UNIVERSITE BRETAGNE OCCIDENTALE, Brest (FR); INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNMENT, Paris (FR); and ETABLISSEMENT FRANCAIS DU SANG (EFS), La Plaine Saint Denis (FR)
Appl. No. 17/043,100
Filed by INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST, Brest (FR); UNIVERSITÉ DE BRETAGNE OCCIDENTALE, Brest (FR); INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, Paris (FR); and ETABLISSEMENT FRANÇAIS DU SANG (EFS), La Plaine Saint Denis (FR)
PCT Filed Mar. 28, 2019, PCT No. PCT/EP2019/057835
§ 371(c)(1), (2) Date Sep. 29, 2020,
PCT Pub. No. WO2019/185778, PCT Pub. Date Oct. 3, 2019.
Claims priority of application No. 18305357 (EP), filed on Mar. 29, 2018; and application No. 18306789 (EP), filed on Dec. 21, 2018.
Prior Publication US 2021/0017584 A1, Jan. 21, 2021
Int. Cl. C12Q 1/689 (2018.01); C12Q 1/686 (2018.01)
CPC C12Q 1/689 (2013.01) [C12Q 1/686 (2013.01); C12Q 2600/118 (2013.01)] 4 Claims
 
1. A method of preventing pulmonary colonization/infection by P. aeruginosa (Pa) in a subject suffering from cystic fibrosis (CF) comprising:
predicting the risk of developing pulmonary colonization/infection by P. aeruginosa by measuring the absolute abundance of Porphyromonas catoniae at different times in biological samples obtained from said subject, wherein no bacterial species other than Porphyromonas catoniae is measured;
detecting a decrease over time in the absolute abundance of Porphyromonas catoniae in the subject, thus the subject having a high risk of developing pulmonary colonization/infection by Pseudomonas aeruginosa; and
administering to the subject a therapeutically effective amount of P. aeruginosa specific antibiotics.